Tumorigenic Cell Reprogramming and Cancer Plasticity: Interplay between Signaling, Microenvironment, and Epigenetics

Stem Cells International
Vittoria PoliAlessio Zippo

Abstract

Accumulating evidences indicate that many tumors rely on subpopulations of cancer stem cells (CSCs) with the ability to propagate malignant clones indefinitely and to produce an overt cancer. Of importance, CSCs seem to be more resistant to the conventional cytotoxic treatments, driving tumor growth and contributing to relapse. CSCs can originate from normal committed cells which undergo tumor-reprogramming processes and reacquire a stem cell-like phenotype. Increasing evidences also show how tumor homeostasis and progression strongly rely on the capacity of nontumorigenic cancer cells to dedifferentiate to CSCs. Both tumor microenvironment and epigenetic reprogramming drive such dynamic mechanisms, favoring cancer cell plasticity and tumor heterogeneity. Here, we report new developments which led to an advancement in the CSC field, elucidating the concepts of cancer cell of origin and CSC plasticity in solid tumor initiation and maintenance. We further discuss the main signaling pathways which, under the influence of extrinsic environmental factors, play a critical role in the formation and maintenance of CSCs. Moreover, we propose a review of the main epigenetic mechanisms whose deregulation can favor the onset of CSC feature...Continue Reading

References

Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·W H LeeW G Nelson
Apr 22, 1993·Nature·S RainierA P Feinberg
Mar 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Muhammad Al-HajjMichael F Clarke
Sep 23, 2003·Proceedings of the National Academy of Sciences of the United States of America·Celina G KleerArul M Chinnaiyan
Dec 12, 2003·Cancer Cell·Sharon GidekelEli Pikarsky
Oct 18, 2005·Cancer Cell·Teresa M HolmRudolf Jaenisch
Jul 25, 2006·Nature·Andrei V KrivtsovScott A Armstrong
Feb 27, 2007·Cell·Tony Kouzarides
Oct 16, 2007·Cancer Cell·Sophia W M BruggemanMaarten van Lohuizen
Dec 19, 2008·Nature·Nick BarkerHans Clevers
Apr 10, 2009·Annual Review of Biochemistry·Cedric R Clapier, Bradley R Cairns
Jul 17, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Mohamed AbdouhGilbert Bernier
Oct 6, 2009·Nature Genetics·Ann-Marie BröskeFrank Rosenbauer
Apr 27, 2010·Nature Cell Biology·Louis VermeulenJan Paul Medema
Jan 21, 2011·Nature·Jane E Visvader
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Aug 13, 2011·Cell Death and Differentiation·J M HeddlestonJ N Rich
Jan 13, 2012·Nature Reviews. Cancer·Long V NguyenConnie J Eaves
Jan 24, 2012·Cell·Andrew D RhimBen Z Stanger
Mar 6, 2012·Cell·Wenjun GuoRobert A Weinberg
May 26, 2012·Cancer Cell·Daniel D De CarvalhoPeter A Jones
May 30, 2012·Nature Reviews. Genetics·Peter A Jones
Jun 12, 2012·Cell·Hans Clevers, Roel Nusse
Oct 12, 2012·Nature Reviews. Cancer·Peter ValentConnie Eaves
Oct 16, 2012·Experimental and Molecular Pathology·Rena MoritaNoriyuki Sato
Oct 31, 2012·Cancer Research·Marco GalloPeter B Dirks
Jan 22, 2013·Nature Cell Biology·Cédric Blanpain

❮ Previous
Next ❯

Citations

Jul 10, 2019·Epigenetics : Official Journal of the DNA Methylation Society·Melanie Ehrlich
Nov 7, 2019·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Alessandro GiovinazzoClaudia Matteucci
Aug 30, 2019·Cancer Communications·Lanqi GongXinyuan Guan
Jan 23, 2020·Stem Cell Reviews and Reports·Plabon Kumar DasFarhadul Islam
Nov 14, 2019·Journal of Clinical Medicine·Claudia De VitisRita Mancini
May 20, 2020·Frontiers in Molecular Biosciences·Archana P ThankamonyRadhika Nair
Aug 6, 2020·Frontiers in Molecular Biosciences·Ritika TiwariBushra Ateeq
Aug 28, 2020·Frontiers in Immunology·Lia WalcherUta Kossatz-Boehlert
Jul 30, 2019·Contrast Media & Molecular Imaging·Orazio SchillaciElena Bonanno
Dec 31, 2019·Journal of Oncology·Nickelas HuffmanVincenzo Coppola
Nov 13, 2018·Frontiers in Oncology·Katia C GenadryCorinne M Linardic
Jun 2, 2020·Frontiers in Molecular Biosciences·Jean Paul Vernot
Dec 4, 2020·Cancers·Bruno Bernardes de JesusSandrina Nóbrega-Pereira
Feb 9, 2021·Frontiers in Genetics·Leonid AdoninNickolai A Barlev
Jul 25, 2021·Cancers·Archana P ThankamonyRadhika Nair

❮ Previous
Next ❯

Methods Mentioned

BETA
nuclear translocation
IECs
methylation profiling
acetylation
transgenic
xenograft

Related Concepts

Related Feeds

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.